Incyte shares rise as third quarter results beat expectations, guidance raised By Investing.com
Update: 2025-10-28
Description
Incyte Corporation's Q3 financial results exceeded expectations, with adjusted earnings of $2.26 per share and total revenue of $1.37 billion, up 20% from last year. Jakafi and Opzelura drove growth, while new treatments like Niktimvo contributed to the strong performance. Incyte raised its full-year outlook and ended the quarter with a $2.9 billion cash reserve, fueling hopes for future innovation. The company plans to submit new data to the FDA and advance clinical trials in oncology and inflammation.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
